Bicycle Therapeutics plc

NasdaqGS:BCYC 株式レポート

時価総額:US$1.4b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Bicycle Therapeutics 過去の業績

過去 基準チェック /06

Bicycle Therapeuticsの収益は年間平均-38.1%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 25.4%割合で 増加しています。

主要情報

-38.1%

収益成長率

40.5%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率25.4%
株主資本利益率-47.2%
ネット・マージン-404.1%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert

May 24

Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

May 10
Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

May 04
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Apr 19
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Jan 04
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Nov 07
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

May 14
The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Mar 31
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Mar 09
Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Aug 31

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Jul 12

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

Jul 05

Bicycle Therapeutics: Trying To Catch This Falling Knife

Apr 17

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

Mar 25

Bicycle Therapeutics: An Oncology Play With Big Potential

Feb 28

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles

Aug 25

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Bicycle Therapeutics EPS misses by $0.05, beats on revenue

May 06

Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Mar 08
Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Feb 23
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

収支内訳

Bicycle Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:BCYC 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 2442-168620
31 Dec 2327-181600
30 Sep 2325-162590
30 Jun 2323-140520
31 Mar 2315-124480
31 Dec 2214-113500
30 Sep 2215-101500
30 Jun 2216-87480
31 Mar 2214-78420
31 Dec 2112-67320
30 Sep 2112-66350
30 Jun 2111-62340
31 Mar 2111-56320
31 Dec 2010-51290
30 Sep 2012-38220
30 Jun 209-37190
31 Mar 209-35160
31 Dec 1914-31150
30 Sep 1910-33130
30 Jun 1911-31110
31 Mar 1911-26100
31 Dec 187-2280
30 Sep 187-2190
31 Dec 172-1660

質の高い収益: BCYCは現在利益が出ていません。

利益率の向上: BCYCは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: BCYCは利益が出ておらず、過去 5 年間で損失は年間38.1%の割合で増加しています。

成長の加速: BCYCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BCYCは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。


株主資本利益率

高いROE: BCYCは現在利益が出ていないため、自己資本利益率 ( -47.23% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘